Browsing Tag
Daiichi Sankyo Company Limited
3 posts
Could Datroway become AstraZeneca and Daiichi Sankyo’s next major oncology franchise after Enhertu?
atroway has received a positive European regulatory recommendation for first-line treatment of metastatic triple-negative breast cancer in patients unable to receive immunotherapy. The decision moves AstraZeneca PLC and Daiichi Sankyo Company, Limited closer to opening a commercially important market while increasing the strategic value of their antibody drug conjugate partnership.
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?
MicroAlgo crashes 20%, Trump Media slips again—here’s why markets panicked
Explore why 25 top U.S.-listed stocks tumbled on April 2 as Trump’s tariff strategy ignited fears of inflation, recession, and global retaliation.